Mysildecard

ਉਤਪਾਦ ਝਲਕ

About Mysildecard

Mysildecard is a generic medicine similar to a reference medicine already authorised in the European Union (EU) called Revatio.

What it is used for

Mysildecard is used to treat adults and children from 1 year of age with pulmonary arterial hypertension (PAH, abnormally high blood pressure in the arteries of the lungs). In adults, it is used in patients with class II (slight limitation of physical activity) or class III (marked limitation of physical activity) PAH.

How it is used

Mysildecard can only be obtained with a prescription and treatment should be started and monitored by a doctor who has experience in the treatment of PAH. Mysildecard is available as tablets (20 mg). In adults, Mysildecard is taken at a dose of 20 mg three times a day. Lower doses of Mysildecard may be needed in patients taking some medicines that affect the way Mysildecard is broken down in the body. In children aged one to 17, the recommended dose is 20 mg three times a day in those over 20 kg. Higher doses should not be used. In children weighing less than 20 kg the maximum recommended dose would be 10 mg three times a day but Mysildecard can only be used when a 20 mg dose is to be given. For lower doses, other medicines containing sildenafil should therefore be used.

How it works

PAH is a debilitating disease where there is severe constriction (narrowing) of the blood vessels of the lungs. This leads to high blood pressure in the vessels taking blood from the heart to the lungs and reduces the amount of oxygen that can get into the blood in the lungs, making physical activity more difficult. The active substance in Mysildecard, sildenafil, belongs to a group of medicines called ‘phosphodiesterase-type-5 (PDE5) inhibitors’, which means that it blocks the PDE5 enzyme. This enzyme is found in the blood vessels of the lungs. When it is blocked, a substance called ‘cyclic guanine monophosphate’ (cGMP) cannot be broken down, so that it remains in the vessels where it causes relaxation and widening of the blood vessels. In patients with PAH, sildenafil widens the blood vessels of the lungs, which lowers the blood pressure and improves symptoms.

Active substance: sildenafil

Source: EMA EPAR